Euro Pacific Asset Management LLC Purchases 121,375 Shares of Novo Nordisk A/S $NVO

Euro Pacific Asset Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 35.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 467,452 shares of the company’s stock after acquiring an additional 121,375 shares during the quarter. Novo Nordisk A/S accounts for about 1.6% of Euro Pacific Asset Management LLC’s holdings, making the stock its 21st biggest position. Euro Pacific Asset Management LLC’s holdings in Novo Nordisk A/S were worth $17,179,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth $25,000. WealthCollab LLC grew its holdings in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Wolfe Research initiated coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $50.29 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a 50-day moving average of $46.09 and a 200-day moving average of $45.83. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The company has a market cap of $224.56 billion, a P/E ratio of 11.81, a P/E/G ratio of 4.70 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. Equities research analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.